Silicon Laboratories Inc.

What they do

Silicon Labs designs analog-intensive, mixed-signal integrated circuits and software platforms for Internet of Things applications, built on standard CMOS process technology. The company is fabless, relying on third-party fabricators in Asia, and to a lesser extent the U.S. and Europe, to manufacture wafers, and on third parties in Asia to assemble, package, and test devices. Products address connected home and security, industrial automation and control, smart metering, smart lighting, commercial building automation, consumer electronics, asset tracking, and medical instrumentation, grouped into Industrial & Commercial and Home & Life markets.

Revenue drivers

• Industrial & Commercial — The larger segment, at $135 million of second-quarter fiscal 2026 revenue, up 23% year-over-year, covering industrial automation, smart metering, commercial building automation, and related applications.
• Home & Life — The smaller segment, at $93 million of second-quarter fiscal 2026 revenue, up 12% year-over-year, covering connected home, security, consumer electronics, and life/medical applications.
• Medical — Called out as achieving record quarterly revenue, up 78% year-over-year in the second quarter of fiscal 2026, within the broader application portfolio.
• Wireless IoT platform and ecosystem — Revenue comes from secure, low-power wireless SoCs plus development tools and ecosystem support; management cited accelerating bookings, new orders, opportunity funnel, and design wins.

Recent performance

Second-quarter fiscal 2026 revenue was $228 million, up 18% year-over-year and up from $213.5 million in the prior quarter. GAAP gross margin was 61.6% and non-GAAP gross margin was 61.9%. GAAP operating loss was $11 million and GAAP diluted loss per share was $(0.32), while non-GAAP operating income was $27 million and non-GAAP diluted EPS was $0.71, up 545% year-over-year. Distributor and end-customer inventory declined in the quarter. For the six months ended July 4, 2026, the company incurred $20.8 million of merger-related costs.

Strategy

The company's stated direction centers on completing its pending merger with Texas Instruments, announced February 4, 2026, under which each outstanding share will convert into $231.00 in cash and Silicon Labs will survive as a wholly-owned TI subsidiary. Stockholders approved the merger agreement on April 30, 2026, and closing is expected in the first half of 2027 subject to regulatory approvals. During the pendency, the company continues to invest in its low-power wireless platform, ecosystem, and design-win funnel, and reported accelerating bookings and design wins in the latest quarter. Silicon Labs has suspended forward-looking guidance because of the pending acquisition. It continues to incur financial advisory, legal, and accounting costs related to the merger.

Risks

• Merger completion risk — The merger with Texas Instruments may not close within the expected first-half 2027 timeframe, or at all, and required regulatory approvals remain outstanding.
• Pendency-period restrictions — While the merger agreement is in effect, Silicon Labs is subject to restrictions on its business activities and the agreement limits its ability to pursue alternative transactions.
• Tariffs and trade barriers — The company states that tariffs, trade restrictions, and other barriers to international trade could materially and adversely affect its business, financial condition, and results of operations.
• Component shortages and supply concentration — Silicon Labs is fabless and depends on third-party manufacturers, assemblers, and test providers concentrated in Asia, and cites risks from shortages of memory and other key components.

Outlook

Management suspended forward-looking guidance due to the pending acquisition by Texas Instruments. The company said its second-quarter revenue growth, bookings, opportunity funnel, and design wins reinforce what it calls a durable growth trajectory. Closing of the merger is expected in the first half of 2027, subject to stockholder approval already obtained and receipt of required regulatory approvals. Merger-related costs are expected to continue and could be significant prior to completion.